The prescription started.
The patient stopped.
28.4% of buprenorphine patients discontinue in the first month. Virtual prescribing solved access. It did not solve retention. Continuum is the missing layer: episode continuity management for SUD treatment.
Two-thirds never stabilize.
The clinical evidence for buprenorphine is strong. The retention evidence is not. 28.4% of patients discontinue treatment in the first month. By six months, 64.6% are gone. The median time in treatment for a first episode is 77 days.
This is not a medication failure. Buprenorphine works when patients stay on it. It is a continuity failure. The system that prescribes the medication does not manage the episode.
Every dropout costs you twice.
An untreated or undertreated SUD case costs employers an estimated $700,000 across healthcare, lost productivity, disability, and replacement. 75% of employers with 500+ employees have at least one member with SUD. Treatment defrays costs by 40% or more, but only if patients stay in treatment long enough to stabilize.
The 30-day cliff means most of that investment is lost before it has time to return value. You are paying for prescriptions that start but do not persist.
$438 billion in annual employer costs tied to substance use disorders. The treatment exists. The retention does not.
Virtual prescribing is table stakes.
There are 16 virtual SUD solutions on the market. The Peterson Health Technology Institute assessed them and found: they are as effective as usual care. They improve retention by 13 additional days over six months. They do not increase treatment initiation. They do not reduce cost.
The reason is structural. Every existing virtual MAT provider optimizes for prescription access. None of them manage the episode. The prescription is a single touchpoint in a treatment arc that spans months. Without structured continuity across that arc, access alone does not convert to retention.
Designed to manage the episode, not just the prescription.
Continuum is a virtual-first SUD treatment program where the unit of delivery is the treatment episode, not the prescription encounter. Each patient will have a named clinical navigator who owns the episode from intake through 12-month maintenance. The pilot launches in Kentucky in 2026.
Four things that will make this different
Named navigator continuity. One navigator. One patient. Every episode. The navigator who coordinates your induction is the same navigator who picks up the phone 14 months later. That continuity produces a longitudinal dataset no episodic model can replicate.
Structured IOP. Nine hours per week of virtual intensive outpatient programming. CBT, motivational interviewing, relapse prevention, psychoeducation. Not a prescription and a follow-up. A clinical program.
Buprenorphine prescribing via permanent telehealth pathway. DEA/HHS finalized the permanent rule for buprenorphine telemedicine. Audio-video or audio-only. No in-person requirement at initiation. This is the regulatory foundation, not a temporary flexibility.
Measured outcomes, reported to you. AUDIT-C, DAST-10, PHQ-9, GAD-7 at intake, discharge, and 90 days. Retention metrics. Completion rates. Reported quarterly to the employer in aggregate. You will know whether the care worked.
From intake to maintenance, one continuous thread.
The navigator thread is continuous across all five phases. If the patient relapses at month 14, the same navigator re-engages. The episode model does not reset. It extends.
Navigator continuity changes retention.
Recovery peer navigators improve clinical retention, particularly for patients with sociodemographic factors correlated with discontinuation. Physician continuity of care is a key predictor of retention in medication-assisted treatment. Interdisciplinary care consisting of buprenorphine combined with behavioral health and care management is necessary to increase retention likelihood.
Digital monitoring tools improve retention in stepped-wedge cluster RCTs. mHealth combined with patient navigation protocols improves linkage and early retention. The evidence base for structured continuity is growing. The evidence base for prescription-only virtual models plateauing at 13 additional days is already here.
Falsification criteria
If a Continuum-managed cohort does not achieve 90-day retention rates above 65%, compared to the national baseline of 48.4% (PubMed 38400724, 10-year buprenorphine retention analysis), the model does not work. We will publish the result either way.
The math on retention.
Sustained buprenorphine treatment reduces total healthcare costs by 40% or more. The cost of untreated SUD is $700,000 per case across the employer's total burden. The cost of treatment that retains patients through stabilization is a fraction of that.
Continuum's pricing will be structured as an enhanced fee-for-service model with a capped performance guarantee. You pay for the treatment. We guarantee the retention. If readmission exceeds the threshold in a cohort, we credit the management fee.
What exists. What Continuum delivers.
Continuum capabilities reflect the pilot model. Competitor capabilities based on public information as of May 2026.
| Capability | Continuum | Bicycle Health | Boulder Care | Ophelia | Workit |
|---|---|---|---|---|---|
| Episode management | ● | ○ | ○ | ○ | ○ |
| Named navigator continuity | ● | ○ | ● | ○ | ○ |
| Structured virtual IOP | ● | ○ | ○ | ○ | ○ |
| Employer outcome reporting | ● | ○ | ○ | ○ | ○ |
| Retention guarantee | ● | ○ | ○ | ○ | ○ |
| Buprenorphine prescribing | ● | ● | ● | ● | ● |
| Virtual-first | ● | ● | ● | ● | ● |
Competitor capabilities based on publicly available information as of May 2026. Virtual MAT programs prescribe buprenorphine. Continuum manages the episode.
What you do. What you get.
What you do: Almost nothing. Identify Continuum as a benefit option in SUD communications. Provide a warm referral pathway from your EAP or care management team. That is the full implementation.
What you get: Quarterly aggregate retention and outcome reports. Navigator accountability metrics. Completion rates by episode phase. Performance guarantee tracking. A clinical program you can point to at renewal that demonstrates you are governing the SUD population, not just covering the prescription.
Integration
Continuum operates alongside your existing carrier and benefits structure. We do not process claims or adjudicate benefits. We do not replace your EAP. We handle the high-acuity SUD cases that EAPs and standard networks are not designed to manage through a full treatment episode.
90 days. Measured. No risk.
Continuum is accepting pilot partners for its Kentucky launch. The pilot is designed to prove the model on a defined population before scaling.
What we will deliver
- Full episode management for referred SUD members
- Named navigator assigned within 48 hours of referral
- Buprenorphine induction and stabilization
- Structured virtual IOP (9 hrs/week)
- Outcome measurement at intake and 90 days
- Quarterly aggregate report to your benefits team
What you commit to
- Identify Continuum in SUD benefit communications
- Provide a referral pathway from EAP or care management
- Designate a benefits contact for reporting
- No technology integration required
- No change to your existing carrier or network
- No minimum volume commitment
A conversation your book needs to have.
Your self-funded clients are spending on SUD. Most of them do not know how much, because the spend is distributed across pharmacy, medical, disability, and productivity loss. The number is $700,000 per case. 75% of employers with 500+ employees have at least one.
Continuum will give you a recommendation you can make with confidence: a clinical program with measured outcomes, a performance guarantee, and quarterly reporting that your client can use at renewal. This is not a wellness app. It is a clinical benefit with accountability. The pilot launches in Kentucky in 2026.
For broker partnership inquiries: joe.nalley@showyourwork.health
Answered without hedging.
Telehealth MAT gives you a prescriber on a screen. Continuum gives you a 12-month clinical program with a named navigator, structured IOP, outcome measurement, and employer reporting. The prescription is one component. The episode is the product.
Virtual is the answer to stigma. No parking lot. No waiting room. No visible clinic visits. The member interacts with their navigator and their treatment team from a private location. The employer sees aggregate data only. Individual participation is confidential.
EAPs handle low-acuity behavioral health: outpatient therapy referrals, short-term counseling, crisis calls. SUD requiring buprenorphine induction, structured IOP, and 12-month maintenance is beyond what EAPs are designed to manage. Continuum handles the cases your EAP refers out.
If 30-day readmission exceeds the agreed threshold across a cohort of sufficient size, Continuum credits a percentage of the management fee. The threshold, cohort size, and credit amount are defined in the pilot agreement. Exclusions: AMA discharge, non-SUD readmission. The guarantee is bounded, not open-ended.
Yes. The DEA and HHS finalized a permanent rule for buprenorphine telemedicine prescribing, effective December 31, 2025. Audio-video and audio-only are permitted. No in-person evaluation is required at initiation. This is permanent regulation, not a pandemic-era flexibility.
Continuum was founded by Joe Nalley, who previously built and operated a 13-location SUD and MAT treatment system serving over 30,000 patients. DEA-licensed, SAMHSA-certified, JCAHO-accredited narcotic treatment programs. The operational playbook for this model comes from direct experience, not a business plan.
Sources.
10-year retention analysis of buprenorphine treatment. PubMed 38400724
Recovery peer navigators and clinical retention. PMC 11146239
Physician continuity of care and MAT retention. PubMed 33219064
Models for MAT retention and continuity of care. ASPE/HHS
Virtual SUD solutions assessment, 2025. Peterson Health Technology Institute
SUD costs nearly $700K per case, 2025. Avalere/Axios
State-by-state commercially insured SUD data, 2024. FAIR Health Opioid Tracker
Final telemedicine rule for buprenorphine prescribing, December 2025. DEA/HHS
Buprenorphine telemedicine prescribing guidance. SAMHSA
Digital monitoring tools and retention: Stepped-wedge cluster RCT. PMC 12770919
mHealth + patient navigation protocols. PMC 11780921
National Survey on Drug Use and Health, 2023-2024. SAMHSA NSDUH
Medicaid and CHIP enrollment data, 2025. CMS